Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

ClinicalTrials.gov ID: NCT00790816

Public ClinicalTrials.gov record NCT00790816. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase I trial that has met its study objectives.

Study identification

NCT ID: NCT00790816
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 500 participants

Conditions and interventions

Conditions

Neoplasms, Breast

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2008 (Type not available)
Primary completion: Aug 19, 2016 (Actual)
Completion: Aug 19, 2016 (Actual)
Last update posted: Feb 28, 2018

2008 – 2016

United States locations

U.S. sites: 15
U.S. states: 13
U.S. cities: 15

Facility	City	State	ZIP	Site status
Novartis Investigative Site	Scottsdale	Arizona	85259	—
Novartis Investigative Site	Tucson	Arizona	85724	—
Novartis Investigative Site	Santa Monica	California	90404	—
Novartis Investigative Site	Washington D.C.	District of Columbia	20007	—
Novartis Investigative Site	Fort Myers	Florida	33916	—
Novartis Investigative Site	Atlanta	Georgia	30341	—
Novartis Investigative Site	Detroit	Michigan	48202	—
Novartis Investigative Site	Lebanon	New Hampshire	03756	—
Novartis Investigative Site	Buffalo	New York	14263	—
Novartis Investigative Site	Durham	North Carolina	27710	—
Novartis Investigative Site	Cleveland	Ohio	44106	—
Novartis Investigative Site	Greenville	South Carolina	29605	—
Novartis Investigative Site	Memphis	Tennessee	38120	—
Novartis Investigative Site	Nashville	Tennessee	37203	—
Novartis Investigative Site	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00790816, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 28, 2018 · Synced Oct 26, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00790816 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →